Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun 1;2(3):520-524.
doi: 10.1002/jha2.242. eCollection 2021 Aug.

Safety and immunogenicity of a first dose of SARS-CoV-2 mRNA vaccine in allogeneic hematopoietic stem-cells recipients

Patrice Chevallier  1   2 , Marianne Coste-Burel  3 , Amandine Le Bourgeois  1 , Pierre Peterlin  1 , Alice Garnier  1 , Marie C Béné  2   4 , Berthe-Marie Imbert  3 , Thomas Drumel  3 , Steven Le Gouill  1 , Philippe Moreau  1 , Beatrice Mahe  1 , Viviane Dubruille  1 , Nicolas Blin  1 , Anne Lok  1 , Cyrille Touzeau  1 , Thomas Gastinne  1 , Maxime Jullien  1 , Sophie Vanthygem  1 , Thierry Guillaume  1   2
Affiliations

Safety and immunogenicity of a first dose of SARS-CoV-2 mRNA vaccine in allogeneic hematopoietic stem-cells recipients

Patrice Chevallier et al. EJHaem. .

Abstract

This was a monocentric prospective study testing the efficacy and safety of a first injection of BNT162b2 (Pfizer-BioNTech) in 112 Allo-HSCT patients. Antibody response to SARS-CoV-2 spike protein receptor-binding domain was tested at the time of the second injection (Roche Elecsys). The study also included a non-randomized control arm of 26 healthy controls. This study shows that a first dose of SARS-CoV-2 messenger RNA vaccine is safe and provides a 55% rate of seroconversion in allotransplanted patients compared to 100% for the controls (p < 0.001). Factors influencing the absence of response in patients were recent transplantation (<2 years), lymphopenia (<1 × 109/L) and immunosuppressive treatment or chemotherapy at the time of vaccination.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

FIGURE 1
FIGURE 1
Anti‐SARS‐CoV‐2 S titers (with median value) after the first vaccine injection: comparison between patients for whom follow‐up after transplant was <1 year (y) versus between 1 and 2 years versus >2 years versus controls
See this image and copyright information in PMC

References

    1. Walsh EE, Frenck RW, Jr, Falsey AR, Kitchin N, Absalon J, Gurtman A, et al. Safety and immunogenicity of Two RNA‐based covid‐19 vaccine candidates. N Engl J Med. 2020;383(25):2439–2450. - PMC - PubMed
    1. Shah V, Ko Ko T, Zuckerman M, Vidler J, Sharif S, Mehra V, et al. Poor outcome and prolonged persistence of SARS‐CoV‐2 RNA in COVID‐19 patients with haematological malignancies; King's College Hospital experience. Br J Haematol. 2020;190(5):e279–e282. - PMC - PubMed
    1. Passamonti F, Cattaneo C, Arcaini L, Bruna R, Cavo M, Merli F, et al. ITA‐HEMA‐COV investigators. Clinical characteristics and risk factors associated with COVID‐19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol. 2020;7(10):e737–e745. - PMC - PubMed
    1. García‐Suárez J, de la Cruz J, Cedillo Á, Llamas P, Duarte R, Jiménez‐Yuste V, et al. Impact of hematologic malignancy and type of cancer therapy on COVID‐19 severity and mortality: lessons from a large population‐based registry study. J Hematol Oncol. 2020;13(1):133. - PMC - PubMed
    1. Agha M, Blake M, Chilleo C, Wells A, Haidar G. Suboptimal response to COVID‐19 mRNA vaccines in hematologic malignancies patients. medRxiv. 2021. 10.1101/2021.04.06.21254949. - DOI - PMC - PubMed